Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.32 EUR | -3.03% | -4.33% | -17.95% |
Apr. 04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Feb. 09 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
Business Summary
Number of employees: 18
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cardiology
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Europe and United States
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 07-07-23 |
David Georges
DFI | Director of Finance/CFO | - | 18-12-31 |
Eytan Breman
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
An Phan
LAW | General Counsel | 49 | 21-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 07-07-23 |
Hilde Windels
CHM | Chairman | 59 | 18-05-06 |
Serge Goblet
BRD | Director/Board Member | - | 07-12-31 |
Director/Board Member | 53 | 22-01-19 | |
Director/Board Member | - | - | |
Director/Board Member | 50 | 20-05-05 | |
Sage Mandel
BRD | Director/Board Member | - | - |
Marina Udier
BRD | Director/Board Member | - | 11-01-10 |
Ami Patel Shah
BRD | Director/Board Member | - | 21-12-07 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 41,428,572 | 38,267,083 ( 92.37 %) | 0 | 92.37 % |
Company contact information
Celyad Oncology SA
Axis Business Park Rue André Dumont 9
1435, Mont-Saint-Guibert
+32 1 039 41 00
http://www.celyad.comSector
Sales per Business
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-17.95% | 14.17M | |
+4.09% | 43.84B | |
+47.81% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |
- Stock Market
- Equities
- CYAD Stock
- Company Celyad Oncology SA